tested for in vitro antibacterial activity against Mycobacterium tuberculosis H37Rv including resistant strains against streptomycin, kanamycin, or isonicotinic acid hydrazide. MICs of these compounds against atypical mycobacteria, Mycobacterium kansasii and Mycobacterium intracellulare were also examined. Structure-activity relationships were found in a series of (acyloxy)alkyl ester derivatives depending
New and known analogues of 2, 2'-dithiodibenzamide were synthesized and tested for various pharmacological actions. This series of compounds was found to inhibit collagen-and adenosine 5'-diphosphate-induced aggregations of blood platelets. 2, 2'-Dithiobis (N-(2-hydroxypropyl) benzamide) (3, KF4939) was one of the most potent compounds in in vitro aggregometry studies. Compound 3 after oral administration also potently inhibited pulmonary thrombosis induced by arachidonic acid injection in mice and platelet aggregation ex vivo in rats. This compound may have clinical value as a new orally active inhibitor of platelet aggregation.